Discover

NAGE
Niagen Bioscience, Inc.
3.33
2 x 2.39
2 x 4.16
bid
ask
+
0.14
4.39%
2 @ 04:00 PM
3.32 -0.01 (0.30%)
Ytd-47.64%
1y-73.53%
3.23
day range
3.35
3.18
52 week range
13.09
Open3.24Prev Close3.19Low3.23High3.35Mkt Cap265.22M
Vol546.89KAvg Vol833.31KEPS0.21P/E15.86Forward P/EN/A
Beta2.08Short Ratio3.35Inst. Own33.09%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg3.90200-d Avg5.731yr Est14.90
Earning
DateForEstimateReportedSurprisesurprise %
2025-08-062025-060.02N/AN/AN/A
2025-05-072025-030.020.040.02100.00%
Upgrade / Downgrade
DateFirmActionFromTo
2025-06-10Canaccord GenuityUpgradeBuyBuy
2025-06-06Roth CapitalUpgradeBuyBuy
2025-05-27Canaccord GenuityUpgradeBuy
2025-04-08HC Wainwright & Co.UpgradeBuyBuy
2025-03-31HC Wainwright & Co.UpgradeBuyBuy
2025-03-17HC Wainwright & Co.UpgradeBuyBuy
Profile
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Insider Holder
DateNameRelationQuantityDescription
2023-09-05CHAMPION RIVER VENTURES, LTD.Director and Beneficial Owner of more than 10% of a Class of Security0.00Purchase
2024-08-19CHAU HOI SHUEN SOLINA HOLLYBeneficial Owner of more than 10% of a Class of Security0.00Purchase
2025-04-08FRIED ROBERT N.Chief Executive Officer1.65MConversion of Exercise of derivative security
2023-11-30GERBER BRIANNAChief Financial Officer28.67KPurchase
2024-12-12JAKSCH FRANK LOUIS JRDirector2.32MSale
2024-08-19LI KA SHINGBeneficial Owner of more than 10% of a Class of Security0.00Sale
Institution Ownership
Report DateOrganizationPositionValuePercentage
2025-03-30Blackrock Inc.3.62M45.56M4.59%
2025-03-30Vanguard Group Inc3.54M44.59M4.49%
2025-03-30Tieton Capital Management, LLC1.99M25.01M2.52%
2025-03-30Shaw D.E. & Co., Inc.1.28M16.17M1.63%
2025-03-30Geode Capital Management, LLC1.18M14.85M1.50%
2025-03-30Arrowstreet Capital, Limited Partnership989.87K12.47M1.26%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2025-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.12M26.74M2.70%
2025-04-29iShares Trust-iShares Russell 2000 ETF1.25M15.77M1.59%
2025-03-30VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund819.38K10.32M1.04%
2025-04-29Fidelity Salem Street Trust-Fidelity Small Cap Index Fund500.41K6.30M0.64%
2025-04-29iShares Trust-iShares Russell 2000 Growth ETF442.77K5.58M0.56%
2025-04-29Invesco Exch-Trd Fd. TRT II-Invesco Dorsey Wright SmallCap Momentum ET325.64K4.10M0.41%